|
Q4 FY2026
As of Jun 30, 2026
|
Q3 FY2026
As of Mar 31, 2026
|
Q2 FY2026
As of Dec 31, 2025
|
Q1 FY2026
As of Sep 30, 2025
|
Q4 FY2025
As of Jun 30, 2025
|
Q3 FY2025
As of Mar 31, 2025
|
Q2 FY2025
As of Dec 31, 2024
|
Q1 FY2025
As of Sep 30, 2024
|
Q4 FY2024
As of Jun 30, 2024
|
Q3 FY2024
As of Mar 31, 2024
|
Q2 FY2024
As of Dec 31, 2023
|
Q4 FY2023
As of Jun 30, 2023
|
Q3 FY2023
As of Mar 31, 2023
|
Q2 FY2023
As of Dec 31, 2022
|
Q1 FY2023
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Investments at fair value | |||||||||||||||
| Control investments | |||||||||||||||
| Non-controlled/affiliated | |||||||||||||||
| Non-control/non-affiliate investments | |||||||||||||||
| Total investments at fair value | |||||||||||||||
| Cash and cash equivalents (restricted cash of $2,812 and $4,282, respectively) | |||||||||||||||
| Receivables for: | |||||||||||||||
| Interest, net | |||||||||||||||
| Other | |||||||||||||||
| Nonrelated Party | |||||||||||||||
| Administration | |||||||||||||||
| Affiliated Entity | |||||||||||||||
| Derivative Assets, at fair value (Note 6) | |||||||||||||||
| Deferred financing costs on Revolving Credit Facility (Note 4) | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Due from broker | |||||||||||||||
| Total Assets | |||||||||||||||
| Liabilities | |||||||||||||||
| Notes | |||||||||||||||
| Public Notes | |||||||||||||||
| Prospect Capital InterNotes® | |||||||||||||||
| Convertible Notes (less unamortized debt issuance costs of $0 and $649, respectively) (Notes 5 and 8) | |||||||||||||||
| Revolving Credit Facility (Notes 4 and 8) | |||||||||||||||
| Due to Prospect Capital Management (Note 13) | |||||||||||||||
| Dividends payable | |||||||||||||||
| Interest payable | |||||||||||||||
| Due to broker | |||||||||||||||
| Accrued expenses | |||||||||||||||
| Other liabilities | |||||||||||||||
| Nonrelated Party | |||||||||||||||
| Administration | |||||||||||||||
| Affiliated Entity | |||||||||||||||
| Derivative Liabilities, at fair value (Note 6) | |||||||||||||||
| Total Liabilities | |||||||||||||||
| Preferred Stock, par value $0.001 per share (766,678,529 and 836,490,792 shares of preferred stock authorized; 68,468,200 and 70,915,937 issued and outstanding, respectively) (Note 9) | |||||||||||||||
| Net Assets Applicable to Common Shares | |||||||||||||||
| Common stock, par value $0.001 per share (1,233,321,471 and 1,163,509,208 common shares authorized; 512,746,556 and 455,902,826 issued and outstanding, respectively) (Note 9) | |||||||||||||||
| Paid-in capital in excess of par (Note 9 and 12) | |||||||||||||||
| Accumulated other comprehensive income (loss) | |||||||||||||||
| Distributions in excess of earnings (Note 12) | |||||||||||||||
| Net Asset Value Per Common Share (Note 16) (in dollars per share) | |||||||||||||||
Loading...
